Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 12, 2016, Pages 1927-1932

  Merlo, Gregory ^a   Graves, Nicholas ^a   Brain, David ^a   Connelly, Luke B ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Clostridium difficile infection; cost effectiveness; economic evaluation; fecal microbiota transplantation; vancomycin

Indexed keywords

METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL FECAL MICROBIOTA TRANSPLANTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FECAL MICROBIOTA TRANSPLANTATION; HEALTH CARE COST; HUMAN; NASODUODENAL FECAL MICROBIOTA TRANSPLANTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT INFECTION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNCERTAINTY; ADVERSE EFFECTS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTESTINE; INTESTINE FLORA; MARKOV CHAIN; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; TIME FACTOR;

ANTI-BACTERIAL AGENTS; AUSTRALIA; CLOSTRIDIUM DIFFICILE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HEALTH CARE COSTS; HUMANS; INTESTINES; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84997482200     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13402     Document Type: Article

References (40)

1. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N. Engl. J. Med. 1994; 330: 257–62.
2. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001; 49: 152–3.
3. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 2002; 97: 1769–75.
4. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–8.
5. Van Gessel H. Measuring the incidence of Clostridium difficile-associated diarhoea in a group of Western Australian hospitals. Healthc. Infect. 2008; 13: 56.
6. Borody T, Fischer M, Mitchell S, Campbell J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev. Gastroenterol. Hepatol. 2015; 9: 1379–91.
7. Kelly CR, Kahn S, Kashyap P et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015; 149: 223–37.
8. Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N. Engl. J. Med. 2013; 368: 407–15.
9. Cammarota G, Masucci L, Ianiro G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 2015; 41: 835–43.
10. Youngster I, Sauk J, Pindar C et al. Fecal microbiota transplant for relapsing clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin. Infect. Dis. 2014; 58: 1515–22.
11. Paramsothy S, Walsh AJ, Borody T et al. Gastroenterologist perceptions of faecal microbiota transplantation. World J. Gastroenterol. 2015; 21: 10907.
12. HEALTHPACT: Health Policy Advisory Committee of Technology Australia and New Zealand. Technology brief update: faecal microbiota transplantation. 2014.
13. Cheng AC, Ferguson JK, Richards MJ et al. Australasian society for infectious diseases guidelines for the diagnosis and treatment of clostridium difficile infection. Med. J. Aust. 2011; 194: 353–8.
14. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 2002; 34: 346–53.
15. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 4.5. Canberra 2015.
16. Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
17. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31: 3163–71.
18. Lee BY, Popovich MJ, Tian Y et al. The potential value of Clostridium difficile vaccine: An economic computer simulation model. Vaccine 2010; 28: 5245–53.
19. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin. Microbiol. Infect. 2012; 18: 282–9.
20. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann. Surg. 2011; 254: 423–9.
21. Australian Bureau of Statistics. 3302.0.55.001 - Life tables, states, terrritories and Australia, 2009-2011. 2012.
22. Department of Health. The Pharmaceutical Benefits Scheme (PBS). Canberra: Commonwealth of Australia, 2016.
23. Pharmacy Direct. Product details: Glycoprep-C Lemon 210 g. 2014.
24. Department of Health. MBS online. 2014.
25. Department of Health. Round 13 (2008-09) cost report – public interim version 6.0, public version 5.2, private version 5.1 and private day hospital facilities (standalone) version 5.1. 2012.
26. Independent Hospital Pricing Authority. Independent Hospital Pricing Authority National Hospital Cost Data Collection Australian Public Hospitals Cost Report 2012–2013, Round 17. Commonwealth of Australia 2015.
27. Queensland Health. Queensland Health Wage Rates. Queensland: The State of Queensland (Queensland Health), 2016.
28. Paramsothy S, Borody TJ, Lin E et al. Donor recruitment for fecal microbiota transplantation. Inflamm. Bowel Dis. 2015; 21: 1600–6.
29. Costello S, Conlon M, Vuaran M, Roberts-Thomson I, Andrews J. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment. Pharmacol. Ther. 2015; 42: 1011–8.
30. Kelly CR, Kahn S, Kashyap P et al. Update on FMT 2015: indications, methodologies, mechanisms and outlook. Gastroenterology 2015.
31. Gastroenterological Society of Australia. GESA position statement on faecal microbiota transplant (FMT). 2015.
32. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin. Infect. Dis. 2014; 58: 1507–14.
33. Stuart RL, Marshall C. Clostridium difficile infection: A new threat on our doorstep. Med. J. Aust. 2011; 194: 331–2.
34. Mitchell B, Ware C, McGregor A, Brown S, Wells A. Clostridium difficile infection in Tasmanian public hospitals 2006 - 2010. Healthc. Infect. 2011; 16: 101–6.
35. Smits LP, Bouter KEC, De Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946–53.
36. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest. Endosc. 2013; 78: 240–9.
37. Smith MB, Kelly C, Alm EJ. Policy: how to regulate faecal transplants. Nature 2014; 506: 290–1.
38. Brandt LJ. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol. Hepatol. 2012; 8: 191–4.
39. Kahn SA, Gorawara-Bhat R, Rubin DT. Fecal bacteriotherapy for Ulcerative colitis: patients are ready, are we? Inflamm. Bowel Dis. 2012; 18: 676–84.
40. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent clostridium difficile infection. Clin. Infect. Dis. 2012; 55: 1652–8.